Intellia Therapeutics
Ticker: NTLA
Drug: Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)
Disease: Hereditary angioedema (HAE)
Topline Date: April 27, 2026
Outcome: PASS
-18.6% from 3 days before to 3 days after
Completed Picks
Topline Results by Round
Each tile shows sponsor movement from three trading days before an event through three trading days after.
Round 3 Picks
1 Completed
Round 2 Picks
5 Completed
Alumis Inc.
Ticker: ALMS
Drug: ESK-001
Disease: Plaque psoriasis
Topline Date: January 6, 2026
Outcome: PASS
+100.4% from 3 days before to 3 days after
Xenon Pharmaceuticals
Ticker: XENE
Drug: Azetukalner (XEN1101)
Disease: Adult focal epilepsy (focal-onset seizures)
Topline Date: March 9, 2026
Outcome: PASS
+34.5% from 3 days before to 3 days after
Cytokinetics Incorporated
Ticker: CYTK
Drug: Aficamten (CY 601)
Disease: Non-obstructive hypertrophic cardiomyopathy (nHCM)
Topline Date: May 5, 2026
Outcome: PASS
+20.2% from 3 days before to 3 days after
oculis
Ticker: OCUL
Drug: OCS-01 (dexamethasone ophthalmic)
Disease: Diabetic macular edema (DME)
Topline Date: May 28, 2026
Outcome: FAIL
+8.5% from 3 days before to 2 days after
Alumis Inc.
Ticker: ALMS
Drug: EryDex (intra-erythrocyte dexamethasone)
Disease: Ataxia-telangiectasia (A-T)
Topline Date: March 30, 2026
Outcome: PASS
-5.8% from 3 days before to 3 days after
Round 1 Picks
7 Completed
Abivax S.A.
Ticker: ABVX
Drug: Obefazimod - (ABTECT)
Disease: Ulcerative colitis
Topline Date: July 22, 2025
Outcome: PASS
+543.0% from 3 days before to 3 days after
DBV Technologies
Ticker: DBVT
Drug: Viaskin Peanut - (VITESSE)
Disease: Peanut allergy
Topline Date: December 17, 2025
Outcome: PASS
+10.3% from 3 days before to 3 days after
AbbVie Inc.
Ticker: ABBV
Drug: RINVOQ (upadacitinib)
Disease: Non-segmental vitiligo (NSV)
Topline Date: July 30, 2025
Outcome: PASS
+3.6% from 3 days before to 3 days after
Levo Therapeutics, Inc. (aquired by ACADIA Pharmaceuticals Inc)
Ticker: ACAD
Drug: Carbetocin (ACP-101) - (COMPASS PWS)
Disease: Prader-Willi syndrome (PWS)
Topline Date: September 24, 2025
Outcome: FAIL
-12.7% from 3 days before to 3 days after
Gossamer Bio, Inc
Ticker: GOSS
Drug: Seralutinib (GB002) - (TORREY/PROSERA)
Disease: Pulmonary arterial hypertension (PAH)
Topline Date: February 23, 2025
Outcome: FAIL
-16.2% from 3 days before to 3 days after
Soligenix
Ticker: SNGX
Drug: HyBryte - (FLASH2)
Disease: Cutaneous T-Cell Lymphoma
Topline Date: April 28, 2026
Outcome: FAIL
-75.2% from 3 days before to 3 days after
Pherin Pharmaceuticals, Inc. acquired by Vistagen (Nasdaq: VTGN) i
Ticker: VTGN
Drug: PH94B - (PALISADE-4)
Disease: Social Anxiety Disorder (SAD)
Topline Date: December 17, 2025
Outcome: FAIL
-82.4% from 3 days before to 3 days after